Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 9:23 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 913–936 of 28,999 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Disease;Neurological Clear all
No Longer Available No phase listed Expanded access

Extension Study of Drisapersen in DMD Subjects

NCT02636686
View directory record Official record
Conditions
Duchenne Muscular Dystrophy
Interventions
Drisapersen
Drug
Lead sponsor
BioMarin Pharmaceutical
Industry
Eligibility
5 Years to 80 Years · Male only
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 24, 2018 · Synced Oct 23, 2026, 9:23 AM EDT
Recruiting Not applicable Interventional

Pain Management Teams Using Whole Health to Optimize Function and Safety in Veterans: The TEAMWORK Trial

NCT07149870
View directory record Official record
Conditions
Chronic Pain
Interventions
Pain Management Team + Whole Health Coach (PMT-WHC), Pain Management Team-Usual Care (PMT-UC)
Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
432 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
5
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Aurora, Colorado + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Oct 23, 2026, 9:23 AM EDT
Completed Phase 4 Interventional Results available

Functional Change and Efficacy of Duloxetine in Patients With Co-Morbid Depression & Soft Tissue Discomfort Syndrome

NCT01035073
View directory record Official record
Conditions
Major Depressive Disorder, Soft Tissue Discomfort Syndrome, Pain
Interventions
Duloxetine
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 75 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 16, 2020 · Synced Oct 23, 2026, 9:23 AM EDT
Active, not recruiting Phase 2 Interventional

NIAGEN and Persistent Chemotherapy-Induced Peripheral Neuropathy

NCT04112641
View directory record Official record
Conditions
Chemotherapy-induced Peripheral Neuropathy
Interventions
Nicotinamide riboside, Placebo capsules
Drug
Lead sponsor
Donna Hammond, PhD
Other
Eligibility
18 Years to 85 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Oct 23, 2026, 9:23 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) for TAK-906 in Participants With Diabetes Mellitus and Gastroparesis (DG) or With Idiopathic Gastroparesis (IG)

NCT03268941
View directory record Official record
Conditions
Diabetes Mellitus and Gastroparesis, Idiopathic Gastroparesis
Interventions
TAK-906 Maleate, Metaclopramide, TAK-906 Maleate Placebo
Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
9
States / cities
Peoria, Arizona • Tucson, Arizona • Little Rock, Arkansas + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 6, 2021 · Synced Oct 23, 2026, 9:23 AM EDT
Terminated Not applicable Interventional

Yoga Therapy in Treating Patients With Malignant Brain Tumors

NCT01234805
View directory record Official record
Conditions
Adult Anaplastic Astrocytoma, Adult Anaplastic Ependymoma, Adult Anaplastic Meningioma, Adult Anaplastic Oligodendroglioma, Adult Brain Stem Glioma, Adult Choroid Plexus Tumor, Adult Diffuse Astrocytoma, Adult Ependymoblastoma, Adult Ependymoma, Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Adult Grade II Meningioma, Adult Medulloblastoma, Adult Meningeal Hemangiopericytoma, Adult Mixed Glioma, Adult Oligodendroglioma, Adult Papillary Meningioma, Adult Pineal Gland Astrocytoma, Adult Pineoblastoma, Adult Pineocytoma, Adult Supratentorial Primitive Neuroectodermal Tumor (PNET), Recurrent Adult Brain Tumor
Interventions
yoga therapy, questionnaire administration, quality-of-life assessment
Procedure · Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 3, 2018 · Synced Oct 23, 2026, 9:23 AM EDT
Completed Phase 3 Interventional

An Inpatient Study of the Effectiveness and Safety of Depakote ER in the Treatment of Mania/Bipolar Disorder

NCT00060905
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Divalproex Sodium (Depakote ER)
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years to 65 Years
Enrollment
370 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
18
States / cities
Cerritos, California • Torrance, California • Washington D.C., District of Columbia + 15 more
Source: ClinicalTrials.gov public record
Updated Aug 4, 2006 · Synced Oct 23, 2026, 9:23 AM EDT
Completed Not applicable Interventional

Silk Protein Microparticle-based Filler for Injection Augmentation

NCT03790956
View directory record Official record
Conditions
Vocal Cord Paralysis Unilateral, Dysphonia, Dysphagia, Oropharyngeal
Interventions
Silk Microparticle Filler Injection
Procedure
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 10, 2023 · Synced Oct 23, 2026, 9:23 AM EDT
Not listed Phase 4 Interventional

Evaluating Sublingual Dexmedetomidine For Moderate To Severe Agitation In Inpatients With Schizophrenia Or Bipolar Disorder

NCT06093451
View directory record Official record
Conditions
Schizophrenia Agitation, Schizo Affective Disorder, Bipolar Disorder, Dexmedetomidine
Interventions
Dexmedetomidine, Lorazepam 2 MG/ML
Drug
Lead sponsor
Temple University
Other
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 23, 2023 · Synced Oct 23, 2026, 9:23 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study of Acetyl Hexapeptide-8 (AH8) in Treatment of Blepharospasm

NCT00942851
View directory record Official record
Conditions
Focal Dystonia
Interventions
Acetyl-Hexapeptide Topical Treatment, placebo
Drug
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 6, 2012 · Synced Oct 23, 2026, 9:23 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Improving the Mental Health and Well Being of Healthcare Providers Through the Transcendental Meditation Technique

NCT05239429
View directory record Official record
Conditions
Burnout, Insomnia, Well Being
Interventions
Transcendental Meditation Technique
Behavioral
Lead sponsor
The Center for Clinical and Cosmetic Research
Other
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Aventura, Florida
Source: ClinicalTrials.gov public record
Updated Nov 21, 2023 · Synced Oct 23, 2026, 9:23 AM EDT
Completed Not applicable Interventional Results available

Predictors of Response in Chronic Stroke

NCT04283253
View directory record Official record
Conditions
Stroke, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases, Cardiovascular Diseases
Interventions
Robot + TTT exercise
Device
Lead sponsor
VA Pittsburgh Healthcare System
Federal
Eligibility
21 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 3, 2022 · Synced Oct 23, 2026, 9:23 AM EDT
Completed Phase 1 Interventional

Amyloid-related Imaging Abnormalities (Microbleeds) in Atypical AD

NCT01723553
View directory record Official record
Conditions
Atypical Alzheimers Disease, Logopenic Variant of Primary Progressive Aphasia (LPA), Posterior Cortical Atrophy (PCA)
Interventions
C-11 PiB
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 21, 2015 · Synced Oct 23, 2026, 9:23 AM EDT
Withdrawn Phase 1 Interventional

A Study to Evaluate the Safety and Tolerability of ABBV-0805 in Patients With Parkinson's Disease

NCT04127695
View directory record Official record
Conditions
Parkinson's Disease
Interventions
ABBV-0805, Placebo ABBV-0805
Drug
Lead sponsor
AbbVie
Industry
Eligibility
Up to 85 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
5
States / cities
Gainesville, Florida • New York, New York • Durham, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 15, 2021 · Synced Oct 23, 2026, 9:23 AM EDT
Completed Phase 1 Interventional

Oral Fecal Transplant in Cirrhosis

NCT03152188
View directory record Official record
Conditions
Hepatic Encephalopathy, Cirrhosis, Liver
Interventions
FMT, Placebo
Drug · Other
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
21 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
2
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated May 19, 2021 · Synced Oct 23, 2026, 9:23 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Biomarkers of Insufficient Sleep and Sleepiness

NCT03130803
View directory record Official record
Conditions
Sleep Deprivation, Insufficient Sleep Syndrome, Sleep Wake Disorders
Interventions
Insufficient Sleep
Behavioral
Lead sponsor
University of Colorado, Boulder
Other
Eligibility
18 Years to 35 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Boulder, Colorado
Source: ClinicalTrials.gov public record
Updated Oct 30, 2020 · Synced Oct 23, 2026, 9:23 AM EDT
Recruiting Phase 2 Interventional

ADAPT Forward 2 - ISA2 - a Study to Evaluate the Safety, Tolerability and Efficacy of Empasiprubart IV Monotherapy in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis

NCT07673627
View directory record Official record
Conditions
AChR-Ab Seropositive Generalized Myasthenia Gravis, Myasthenia Gravis (MG), MG - Myasthenia Gravis, gMG
Interventions
Empasiprubart IV, Placebo IV, Efgartigimod PH20 SC PFS
Biological · Other · Combination Product
Lead sponsor
argenx
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
6
States / cities
Carlsbad, California • Miami, Florida • Las Vegas, Nevada + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 23, 2026, 9:23 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy Evaluation of DOTAREM® in MRI of Central Nervous System (CNS) Lesions

NCT01211873
View directory record Official record
Conditions
Diagnostic Self Evaluation, Central Nervous System Diseases
Interventions
Dotarem (gadoterate meglumine), Magnevist (gadopentetate dimeglumine)
Drug
Lead sponsor
Guerbet
Industry
Eligibility
2 Years and older
Enrollment
416 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
20
States / cities
Birmingham, Alabama • Tucson, Arizona • Indian Wells, California + 14 more
Source: ClinicalTrials.gov public record
Updated Apr 18, 2019 · Synced Oct 23, 2026, 9:23 AM EDT
Completed Phase 3 Interventional Results available

Withdrawal Study to Demonstrate the Maintenance Effect in the Treatment of Non-24-Hour Sleep-Wake Disorder

NCT01430754
View directory record Official record
Conditions
Non-24-Hour Sleep-Wake Disorder
Interventions
tasimelteon, Placebo
Drug
Lead sponsor
Vanda Pharmaceuticals
Industry
Eligibility
Not listed
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
22
States / cities
Phoenix, Arizona • Orange, California • Palo Alto, California + 19 more
Source: ClinicalTrials.gov public record
Updated Oct 10, 2014 · Synced Oct 23, 2026, 9:23 AM EDT
Completed Phase 2 Interventional Results available

Crossover Trial of AD109 in Obstructive Sleep Apnea

NCT04580394
View directory record Official record
Conditions
Obstructive Sleep Apnea
Interventions
AD109, Atomoxetine, R-oxybutynin, Placebo, Digit System Substitution Test
Drug · Diagnostic Test
Lead sponsor
Apnimed
Industry
Eligibility
25 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
7
States / cities
Little Rock, Arkansas • Pomona, California • New Haven, Connecticut + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 31, 2023 · Synced Oct 23, 2026, 9:23 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Evaluation of Vestibular Stimulation to Help Occasional Sleeplessness

NCT00594022
View directory record Official record
Conditions
Insomnia, Sleeplessness, Transient Insomnia
Interventions
Electric stimulation of the Vestibular Nerve - "VirtuSom", Electric stim of the Vestibular Nerve - "VirtuSom" - SHAM
Device
Lead sponsor
Philips Respironics
Industry
Eligibility
21 Years to 50 Years
Enrollment
349 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
6
States / cities
Atlanta, Georgia • New York, New York • Rochester, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 7, 2019 · Synced Oct 23, 2026, 9:23 AM EDT
Terminated Phase 3 Interventional

Treadmill Training at Constant or Different Speeds for People With Traumatic Brain Injury

NCT01419522
View directory record Official record
Conditions
Traumatic Brain Injury, Walking Impairment, Gait Training
Interventions
Gait Training Method
Other
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 16, 2019 · Synced Oct 23, 2026, 9:23 AM EDT
Completed Phase 2 Interventional Results available

MK-3795 (PT2385) for the Treatment of Von Hippel-Lindau Disease-Associated Clear Cell Renal Cell Carcinoma (MK-3795-003)

NCT03108066
View directory record Official record
Conditions
VHL Gene Mutation, VHL, VHL Syndrome, VHL Gene Inactivation, Von Hippel, Von Hippel-Lindau Disease, Von Hippel's Disease, Von Hippel-Lindau Syndrome, Modifiers of, Clear Cell Renal Cell Carcinoma, Clear Cell RCC, ccRCC
Interventions
MK-3795
Drug
Lead sponsor
Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 24, 2024 · Synced Oct 23, 2026, 9:23 AM EDT